Want to see KR:003520 full AI Analyst Report?
Top Page
YUNGJIN PHARM. CO. LTD
(003520)
Select Model
Select Model
Rating:40Underperform
Price Target:
₩907.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak financial performance—especially negative and volatile cash flow alongside a sharp TTM revenue drop and renewed losses. Technical signals also remain bearish, with price below all key moving averages and negative MACD. Valuation provides limited support because the P/E is negative (loss-making) and no dividend yield is available.
Positive Factors
Established pharmaceutical business
Yungjin Pharm has an established operating model spanning pharmaceutical research, development, manufacturing, and commercialization. Its prescription-drug focus and regulated domestic distribution channels provide an enduring platform for serving healthcare demand and supporting product continuity.
Negative Factors
Sharp revenue decline and renewed losses
The sharp TTM revenue contraction and return to operating and net losses show that earnings remain unstable rather than following a dependable recovery path. Continued weakness could reduce reinvestment capacity, impair operating leverage, and make future performance highly dependent on a revenue rebound.
Read all positive and negative factors
Positive Factors
Negative Factors
Established pharmaceutical business
Yungjin Pharm has an established operating model spanning pharmaceutical research, development, manufacturing, and commercialization. Its prescription-drug focus and regulated domestic distribution channels provide an enduring platform for serving healthcare demand and supporting product continuity.
Read all positive factors
YUNGJIN PHARM. CO. LTD (003520) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩173.93B
Dividend YieldN/A
Average Volume (3M)300.34K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth0.60%
EPS Growth-6964.46%
CountryKR
Employees626
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-33.82
Shares Outstanding182,892,730
10 Day Avg. Volume298,992
30 Day Avg. Volume300,338
Financial Highlights & Ratios
PEG Ratio13.62
Price to Book (P/B)4.25
Price to Sales (P/S)1.53
P/FCF Ratio-413.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
YUNGJIN PHARM. CO. LTD Business Overview & Revenue Model
Company Description
Yungjin Pharm. Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. Its products include cephalosporin, antibiotics, drugs for the central nervous system, cardiovascular, endocrine system, urinary system, respirat...
YUNGJIN PHARM. CO. LTD Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
58
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 253.00B | 254.26B | 252.04B | 234.90B | 218.38B | 196.07B |
| Gross Profit | 73.30B | 75.86B | 80.35B | 72.59B | 64.73B | 57.94B |
| EBITDA | 4.48B | 12.20B | 16.87B | 7.65B | -14.30B | -6.56B |
| Net Income | -6.26B | -227.66M | 1.23B | -3.88B | -21.96B | -11.58B |
Balance Sheet | ||||||
| Total Assets | 227.40B | 262.38B | 234.26B | 226.60B | 203.08B | 194.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.59B | 28.43B | 3.44B | 10.21B | 682.25M | 464.57M |
| Total Debt | 77.24B | 93.99B | 65.08B | 66.88B | 39.32B | 13.06B |
| Total Liabilities | 141.24B | 170.93B | 144.45B | 136.97B | 113.21B | 89.21B |
| Stockholders Equity | 86.16B | 91.46B | 89.80B | 89.63B | 89.87B | 104.89B |
Cash Flow | ||||||
| Free Cash Flow | -8.34B | -939.92M | 133.66M | -22.74B | -24.81B | -2.95B |
| Operating Cash Flow | -2.85B | 10.24B | 21.74B | -12.50B | -11.61B | 8.37B |
| Investing Cash Flow | -6.62B | -11.91B | -18.30B | -13.02B | -13.35B | -11.64B |
| Financing Cash Flow | 1.78B | 26.65B | -7.21B | 32.04B | 25.18B | 3.31B |
YUNGJIN PHARM. CO. LTD Technical Analysis
Negative
―
Price Trends
1077.36
Negative
1142.54
Negative
1463.12
Negative
Market Momentum
-30.50
Positive
31.66
Neutral
5.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003520, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1011.50, equal to the 50-day MA of 1077.36, and equal to the 200-day MA of 1463.12, indicating a bearish trend. The MACD of -30.50 indicates Positive momentum. The RSI at 31.66 is Neutral, neither overbought nor oversold. The STOCH value of 5.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003520.
YUNGJIN PHARM. CO. LTD Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩243.17B | 3.39 | ― | 3.64% | 4.13% | 116.32% | |
66 Neutral | ₩225.55B | 10.30 | ― | 4.16% | 0.28% | 16.80% | |
58 Neutral | ₩198.48B | 5.07 | ― | 2.80% | 11.64% | -4.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩212.70B | 59.83 | ― | 0.44% | 11.35% | 204.54% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:004310
Hyundai Pharmaceutical Co., Ltd.
6,880.00
3,159.39
84.92%
KR:005500
Samjin Pharmaceutical Co., Ltd.
19,240.00
174.53
0.92%
KR:008490
Suheung Co. Ltd.
17,850.00
-9,106.65
-33.78%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
567.55
9.78%
KR:033270
KOREA UNITED PHARM, INC.
16,760.00
-1,833.09
-9.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.